benralizumab EGPA
Selected indexed studies
- Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. (N Engl J Med, 2024) [PMID:38393328]
- Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies. (Biomolecules, 2025) [PMID:40305320]
- Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study. (J Autoimmun, 2025) [PMID:40147217]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. (2024) pubmed
- Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies. (2025) pubmed
- Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study. (2025) pubmed
- Benralizumab noninferior to mepolizumab for EGPA. (2024) pubmed
- Long-term effectiveness and safety of benralizumab in EGPA: a 3-year single-center experience. (2025) pubmed
- Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. (2025) pubmed
- Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis. (2024) pubmed
- Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study. (2023) pubmed
- [Successful benralizumab therapy for severe asthma secondary to EGPA refractory to mepolizumab]. (2025) pubmed
- Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes. (2022) pubmed